💉NIH Proposes New Intellectual Property Policy for Cancer Research
Request for Comments: Division of Cancer Prevention Intellectual Property Option to Collaborators
Summary
The National Cancer Institute, an Institute of the National Institutes of Health, Department of Health and Human Services, Division of Cancer Prevention (DCP) is seeking comments on instituting a standard policy on Intellectual Property (IP) developed by certain funding recipients under NCI DCP funding agreements. This standard policy is entitled "The DIVISION OF CANCER PREVENTION INTELLECTUAL PROPERTY OPTION TO COLLABORATORS (IP Option)." The proposed policy, if finalized, shall apply to entities that conduct DCP-funded clinical studies under funding agreements which involve an NCI collaborator that provides its proprietary agent or technology for the DCP-supported studies where this IP Option is included as a term of applicable existing and future funding agreements.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$$ - High
The content discusses the proposed "Division of Cancer Prevention Intellectual Property Option to Collaborators" policy, which outlines intellectual property (IP) rights related to clinical studies funded by the NIH. This impacts business owners and executives in the pharmaceutical and biotechnology sectors, as it creates a standardized approach to IP, potentially facilitating collaborations and offering clearer terms for commercialization of inventions developed during funded studies.